Clinical Trials & Research
Rein Therapeutics Expands Phase 2 IPF Trial to United Kingdom
The NASDAQ-listed clinical-stage biopharma is broadening its orphan pulmonary fibrosis program beyond the U.S. as IPF p…
The NASDAQ-listed clinical-stage biopharma is broadening its orphan pulmonary fibrosis program beyond the U.S. as IPF p…